Stratosvir is pleased to announce the fantastic news that Proven Connect (the translational research arm of Prostate Cancer Research, PCR) has invested in the company. Currently, only 5% of advanced prostate cancer patients respond to immunotherapy, a treatment that is working in other cancer indications. There are those who believe that immunotherapy will never work in this disease. We disagree, and we are thrilled that Proven Connect (Prostate Cancer Research) joins us on our mission. We need to understand why a problem exists and to build appropriate and better therapies to overcome this barrier – this is our joint mantra.  June 2024.